147 related articles for article (PubMed ID: 25468320)
21. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma.
Holtan SG; Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Litzow MR; Gastineau DA; Markovic SN
Br J Haematol; 2006 Jun; 133(6):628-33. PubMed ID: 16704437
[TBL] [Abstract][Full Text] [Related]
22. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma.
Markovic O; Popovic L; Marisavljevic D; Jovanovic D; Filipovic B; Stanisavljevic D; Matovina-Brko G; Hajder J; Matkovic T; Živkovic R; Stanisavljevic N; Todorović M; Petrovic D; Mihaljevic B
Eur J Intern Med; 2014 Mar; 25(3):296-302. PubMed ID: 24565533
[TBL] [Abstract][Full Text] [Related]
23. Absolute lymphocyte count predicts overall survival in follicular lymphomas.
Siddiqui M; Ristow K; Markovic SN; Witzig TE; Habermann TM; Colgan JP; Inwards DJ; White WL; Ansell SM; Micallef IN; Johnston PB; Call TG; Porrata LF
Br J Haematol; 2006 Sep; 134(6):596-601. PubMed ID: 16889618
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
[TBL] [Abstract][Full Text] [Related]
25. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
26. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
27. The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.
Kim C; Lee HS; Min CK; Lee JJ; Kim K; Yoon DH; Eom HS; Lee H; Lee WS; Shin HJ; Lee JH; Park Y; Jo JC; Do YR; Mun YC
Korean J Intern Med; 2015 Sep; 30(5):675-83. PubMed ID: 26354062
[TBL] [Abstract][Full Text] [Related]
28. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
30. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Porrata LF; Gertz MA; Inwards DJ; Litzow MR; Lacy MQ; Tefferi A; Gastineau DA; Dispenzieri A; Ansell SM; Micallef IN; Geyer SM; Markovic SN
Blood; 2001 Aug; 98(3):579-85. PubMed ID: 11468153
[TBL] [Abstract][Full Text] [Related]
31. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
Porrata LF; Ingle JN; Litzow MR; Geyer S; Markovic SN
Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
[TBL] [Abstract][Full Text] [Related]
32. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib.
Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K
Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720
[TBL] [Abstract][Full Text] [Related]
34. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance of absolute lymphocyte count in de novo patients with multiple myeloma].
Cheng XC; Zhang XL; Ye X; Shi XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):624-7. PubMed ID: 22739169
[TBL] [Abstract][Full Text] [Related]
36. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
38. Apheresis instrument settings influence infused absolute lymphocyte count affecting survival following autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma: the need to optimize instrument setting and define a lymphocyte collection target.
Katipamula R; Porrata LF; Gastineau DA; Markovic SN; Moore SB; Greiner C; Burgstaler EA; Padley DJ; Winters JL
Bone Marrow Transplant; 2006 May; 37(9):811-7. PubMed ID: 16532018
[TBL] [Abstract][Full Text] [Related]
39. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia.
Le Jeune C; Bertoli S; Elhamri M; Vergez F; Borel C; Huguet F; Michallet M; Dumontet C; Recher C; Thomas X
Leuk Lymphoma; 2014 Apr; 55(4):855-62. PubMed ID: 23786457
[TBL] [Abstract][Full Text] [Related]
40. Clinical course and prognosis of non-secretory multiple myeloma.
Chawla SS; Kumar SK; Dispenzieri A; Greenberg AJ; Larson DR; Kyle RA; Lacy MQ; Gertz MA; Rajkumar SV
Eur J Haematol; 2015 Jul; 95(1):57-64. PubMed ID: 25382589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]